Vaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting

Independent directors James Breitmeyer and Kevin Finney urged shareholders to vote FOR all six of Vaxart's director nominees on the WHITE proxy card ahead of the July 16 annual meeting. The letter serves as a defense against a dissident shareholder group seeking to replace half of the board and add themselves to the seats. The directors highlighted the board's effectiveness in navigating recent macro challenges, including BARDA stop-work orders and the successful securing of funding for the Phase 2b COVID-19 study. They emphasized that the current board's specific experience in life sciences and drug development is critical for advancing programs and maintaining key partnerships.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.